Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Video content above is prompted by the following:
- What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
- What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
- Discuss shared decision-making when managing patients with APQ4+ NMOSD.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.